University Of Florida
University Of Florida is recorded as a service provider in 4 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 4 of 4 trials · Latest update first
Randomised, double blind, placebo controlled, multicentre study to evaluate the efficacy, safety and tolerability of givinostat in non-ambulant patients with Duchenne Muscular Dystrophy
Sponsor Italfarmaco S.p.A.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Single-Arm, Open-Label Extension Study, Evaluating the Long-Term Safety and Clinical Efficacy of SAR447537 (INBRX-101) in Adults with Alpha-1 Antitrypsin Deficiency (AATD) Emphysema
Sponsor Sanofi AATD Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Double-blind, Randomized, Active-control, Parallel Group Study to Assess the Pharmacokinetics, Pharmacodynamics, Immunogenicity, and safety of SAR447537 (INBRX-101) Compared to Plasma Derived Apha1-Proteinase Inhibitor (A1PI) Augmentation Therapy in Adults with Alpha-1 Antitrypsin Deficiency (AATD) Emphysema
Sponsor Sanofi AATD Inc.
- Start (EU)
- Latest update
- Estimated end
A Prospective Phase III Multi-center, 2-Year Placebo Controlled, Double Blind Study to Evaluate the Efficacy and Safety of “Kamada-AAT for Inhalation” 80 mg per Day in Adult Patients with Congenital Alpha-1 Antitrypsin Deficiency with Moderate and Severe Airflow Limitation (40% ≤ FEV1 ≤ 80% of predicted; FEV1/SVC ≤ 70%), Followed by a 2-Year Open- Label Extension
Sponsor Kamada Ltd.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for University Of Florida?
The 2026-10-09 snapshot links University Of Florida to 4 distinct CTIS trials. Recorded services include Laboratory services, Data Analysis, PK Analysis and PiM. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for University Of Florida?
The most frequently recorded therapeutic areas are Genetic and Congenital Disorders, Musculoskeletal, Neurology, Respiratory. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to University Of Florida conducted?
The linked trials record locations in 12 countries, including Sweden, Spain, Ireland, Poland, Belgium. These are trial locations, not confirmed office locations or countries where University Of Florida delivered services.
What can this page tell me about University Of Florida's trial experience?
Browse 4 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under University Of Florida. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- University Of Florida